3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
72
Neoplasms
7
Neoplasm Metastasis
7
Breast Diseases
5
Neoplasms by Site
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasm Female
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Granulosa Cell Ovarian Cancer
1
Fallopian Tube Neoplasms
1
Endometrial Stromal Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Lobular
1
Carcinoma, Ductal, Breast
1
Breast Carcinoma In Situ
1
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
25
130-nm albumin-bound paclitaxel
24
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
Doxorubicin
20
olaparib
19
Taxes
19
Biopsy
19
Albumin-Bound Paclitaxel
19
Drug Therapy
16
atezolizumab
13
Nivolumab
13
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Anastrozole
×
1 year
×
Clear all
NCT04556773
2025-12-17
DB-08
AstraZeneca
Phase 1
Active not recruiting
138 enrolled